

# Use of Alginates and for Management of Symptoms of and Their Impact on Quality of Life


By Valerie J. Arklie,  
Shirley Herlick  
AND Kerron Kidd

**M**alignant wounds develop in 10 per cent of cancer clients. They are characterized by visible changes in the skin, with cancer cells protruding through the dermal layer. Wounds are not only cutaneous—sinuses may drain from areas of necrosis or from erosion into organs such as the bowel. Symptoms such as copious exudates, bleeding, infection, pain, and foul odour can occur.<sup>1</sup> This can be devastating for both clients and their families, affecting quality of life. The right choice of dressing can help control exudate and improve quality of life.

Alginates and foams have proven to be effective for the symptoms of malignant wounds.<sup>2</sup> The literature states alginate is a natural polymer derived from brown seaweed.<sup>3</sup> Alginates act via an ion exchange mechanism, absorbing exudate and forming a non-adherent gel.<sup>4</sup> Alginates are designed to absorb large amounts of discharge<sup>5,6,7</sup> and can be changed every two to seven days.<sup>8,9</sup> Alginates transport excess exudate from the skin surface to prevent maceration. They are strong when wet and are fibre-free.

Alginates may influence wound healing in a number of ways not yet fully understood.<sup>5,6,7,10,11,12</sup> In 1999, Bowler et al. showed that alginates and hydrofibres sequester and bind bacteria.<sup>13</sup> The use of an alginate showed that healing time was significantly faster in Stage III or IV pressure ulcers.<sup>14</sup> In a multicentred, randomized controlled trial comparing an alginate dressing to a hydrofibre dressing in the management

of various wound types, researchers found that the alginate dressing demonstrated a statistically significant faster healing time when compared to the hydrofibre.<sup>15</sup> Alginates contain calcium and sodium. It is well established that calcium plays an important role in wound healing and it is possible that calcium in the wound fluid, some of which is released from the alginate dressing, may modulate the healing.<sup>16</sup> Perhaps sodium's ability to kill bacteria or other unique properties of calcium alginates may be influencing this outcome. Further study is warranted in this area.



"Window-framed" foam dressing.

However, alginates are designed to have a secondary dressing.<sup>4</sup> Foams have proven effective as a secondary dressing with alginates, increasing the absorption of fluid. Many foam products are water resistant<sup>3</sup> and can be left on for up to seven days.<sup>4</sup> Foams come in either a polyurethane polymer or a hydrocellular construction.<sup>17</sup> Both

have been shown to be equally effective.<sup>18</sup> Most are hydrophillic, which means they will absorb exudate and wick into the attached backing, thus keeping the skin dry.<sup>19,20</sup> Exudate management depends critically on venting excess fluid.<sup>21</sup> Because some foams are permeable to air and moisture, it is important not to cover them but only to "window frame" the dressing (see photo 1) with tape to allow maximum evaporation.<sup>22</sup> Foams are 80 per cent air, offering cushioning, insulation, and absorbability.<sup>3</sup>

Let us examine how alginates and foams affect each symptom of malignant wounds.



For two case studies comparing the outcomes and cost-effectiveness of alginate and foam dressings, please visit the *Wound Care Canada* section of the CAWC Web site at [www.cawc.net](http://www.cawc.net).



# Foams

## Chronic Malignant Wounds

### Exudate and Periwound Skin

Increased exudate in malignant wounds is caused by an excessive permeability of the tumour to fibrinogen and plasma colloids, the secretion of a vascular permeability factor, and the general inflammatory response.<sup>23</sup> Alginates and foams, when combined, are excellent for managing increased exudate.<sup>24</sup> Alginates absorb up to 20 times their weight, and foams can absorb from 1,000 to 3,000 cc per square metre per day.<sup>3</sup> Foam wicks away moisture<sup>19</sup> and alginate transports exudate away from the wound;<sup>3</sup> therefore, the use of both together helps prevent maceration of periwound skin.

Periwound skin can be affected by a number of factors, including cleansing solutions and procedures used for cleansing and maceration from wound exudate, absorption and evaporation of moisture, and adhesive products that strip the skin.<sup>25,26</sup> Application of protective barrier products such as pastes, ointments, solid barrier sheets or alcohol-free liquid barrier films helps to protect and maintain the periwound skin. Liquid barriers that contain no alcohol provide effective protection to the periwound skin.<sup>25</sup> Choosing an adhesive product that is skin-friendly to affix the dressing decreases the pain and trauma associated with adhesive removal.

### Bleeding

Bleeding in malignant wounds is caused by the absence of platelets and the abundance of friable capillaries. Because bleeding occurs easily, it is essential that dressings do not adhere or cause trauma. Alginates are ideal for bleeding wounds as they have hemostatic properties.<sup>1</sup> They do not adhere when saturated, allowing for easy removal.<sup>3</sup> Foam dressings are also effective for bleeding wounds because they are highly absorbent and non-adherent.<sup>4</sup>

### Malodour and Infection

The presence of a malodorous wound is a constant reminder to the patient of the underlying disease and often contributes to diminished self-esteem, embarrassment, depression, and social isolation.<sup>25</sup> Wound malodour is caused mainly by heavy bacterial colonization, both aerobic and anaerobic, that occupies the moist environment, necrotic tissue, exudate and dressings.<sup>27</sup> Debridement of the sloughed and necrotic tissue is not recommended in malignant wounds because of the tendency for these wounds to bleed.<sup>24</sup>

Appropriate systemic antimicrobial therapy is essential when the signs and symptoms of infection extend beyond the wound margin or the wound probes to bone.<sup>28</sup> Antibiotics that are effective against anaerobes may be applied topically to control bacteria and produce surface deodorization and odour control.<sup>27,29</sup> Topical antimicrobial agents for local symptoms and signs of infection or increased bacterial burden such as ionized silver dressings, cadexomer iodine and topical antibacterials may help to reduce bacterial colonization and treat the wound surface.<sup>28</sup>

Both foams and alginates can be used on infected wounds.<sup>22</sup> Foams provide a bacterial barrier and are non-occlusive.<sup>3</sup> Effective containment of wound drainage by the use of semi-occlusive dressings, which are sealed at the wound edge, help to control wound odour. Adhesive foams, absorbent hydrofibres, alginates or hypertonic dressings, together with semi-occlusive dressings, are effective in controlling odour when sealed at the wound edge.<sup>30</sup> Frequent dressing changes, quick containment, and removal of soiled dressing materials will help to control odour.

Charcoal-impregnated dressings may be helpful to absorb gases and filter odour from the wounds.<sup>25</sup> The use of local external deodorizers, air fresheners and other fragrances close to the person or in the room

**Valerie J. Arklie, RN, BN,** is a Home Care Nurse in Winnipeg, MB. She is a Wound Care Consultant on the Wound Care Best Practice Team of the Winnipeg Regional Health Authority.

**Shirley Herlick, RN, BN, MScA,** works as a Wound Care Consultant in the role of 3M Skin Health Account Representative and as a casual in Emergency at Health Sciences Centre, in Winnipeg, MB. For 31 years, she has worked in a variety of roles and settings at this tertiary care hospital, including Manager of a Trauma Unit, ER, Nutrition Support Nursing, Vascular Access Consultant, ICU, Manager of Special Procedures in Radiology and OR. She also worked as a CNS for Medicine and Surgery at Concordia Hospital in Winnipeg. She is a member of the CAWC.

**Kerron Kidd, RPN,** was the Wound Resource Nurse and Resident Care Co-ordinator at Poseidon Care Centre, one of the personal care homes of Central Care Corporation. She has 35 years of nursing in a variety of settings throughout the health-care system, with the last 20 years being in geriatric settings. Currently, she is the acting Director of Resident Care in this Poseidon Care Centre.

often merely mask odours, aggravating sensitivity to odour.<sup>30</sup> The use of odour absorbers such as vinegar, baking soda, and charcoal briquettes in the room have been reported to assist with odour reduction within the environment.<sup>29,30</sup>

### Pain

There are a number of mechanisms that can cause pain in patients with malignant wounds. There are many pharmacological and non-pharmacological interventions available, such as regular and bolus systemic pain medications, local anaesthetics, and relaxation strategies. As well, techniques used in caring for the person such as pain-reducing dressings, skin barriers, pressure relief surfaces, and lifting and turning strategies are interventions that can help reduce pain.<sup>25</sup>

Alginates and some foams prevent pain because they do not adhere to wounds. Alginates must be moist to be removed.<sup>4</sup> Foams are approximately 0.5 cm thick and provide a cushion to reduce pressure and provide comfort to a painful area.<sup>31</sup> Alginates and foams can be left on for two to seven days, thus reducing the pain and trauma associated with frequent dressing changes.<sup>8,9</sup>

The best approach to pain management is an individualized plan of care for each person. It involves a careful assessment of the wound and the pain as well as identification of the impact the pain is having on the person's activities of daily living and quality of life.<sup>24,25</sup>

### Quality of Life

The symptoms of malignant wounds can be overwhelming for clients. More than 30 per cent of clients

with malignant wounds have psychosocial problems resulting from the wound.<sup>34</sup> Grocott states society is repulsed by uncontrolled body fluids and resulting odours, causing clients to hide away.<sup>21</sup> Disfiguring wounds or bulky dressings can cause body image changes, which promote social isolation often resulting in depression.<sup>32</sup> Pain resulting from the wound and from painful dressing changes can be very debilitating. Since these malignant wounds rarely heal, their management is based on symptom control, promoting comfort and maintaining or improving the patient's quality of life (see Figure 1).<sup>33</sup>

Alginates and foam dressings are effective for large amounts of exudate and therefore can assist in preventing depression and social isolation.<sup>21</sup> Alginates and foams are thin, self-adhesive and conform well to contours. This increases the freedom to carry out normal daily activities.<sup>33</sup> Many types of foam are flesh-toned, assisting with body image changes. Alginates and foams are effective in reducing pain in malignant wounds, therefore improving quality of life.


Social support from family and staff are also extremely important in the client's quality of life. Research shows such support alleviates social isolation resulting from malignant wounds.<sup>32</sup>

Alginates and foams are highly effective dressings for chronic malignant wounds. They control the symptoms, increase the quality of life for clients coping with cancer, and are cost-effective. ☺

### References

1. Barton P, Parslow N. Malignant wounds: Holistic assessment and management. In Krasner DL, Rodeheaver GT, Sibbald RG, (eds.). *Chronic Wound Care: A Clinical Source Book for Healthcare Professionals*, Third Edition. Wayne, PA: HMP Communications. 2001:699-710.
2. Grocott P. The palliative management of fungating malignant wounds. *Journal of Wound Care*. 2000;9(1):4-9.
3. Advanced Medical Solutions Group. Alginates: A key AMS technology. 2001 Available online at [www.admedsol.com/technology/alginate.html](http://www.admedsol.com/technology/alginate.html) and [www.admedsol.com/technology/foam.html](http://www.admedsol.com/technology/foam.html). Accessed May 27, 2003.
4. Somers SS, et al. The Flexipore 6000 Membrane as a wound dressing for use in accident and emergency department. *Arch Emerg Med*. 1992;9:246-248. Available online at [www.npc.co.uk/nurse\\_prescribing/bulletins/modWound2.2htm](http://www.npc.co.uk/nurse_prescribing/bulletins/modWound2.2htm). Accessed May 27, 2003.
5. Thomas S. Alginate dressings in surgery and wound management: Part 1. *Journal of Wound Care*. 2000;9(2).
6. Thomas S., Alginate dressings in surgery and wound management: Part 2. *Journal of Wound Care*. 2000;9(3):115-9.
7. Thomas S. Alginate dressings in surgery and wound management: Part 3. *Journal of Wound Care*. 2000;9(4):163-166.

references continued on page 47



## Use of Alginates and Foams for Management of Symptoms of Chronic Malignant Wounds and Their Impact on Quality of Life

*continued from page 12*

8. Whiteley MS, et al. Sutureless closure of surgical wounds using the Flexipore 6000 Membrane dressing. First European Conference on Advances in Wound Management. 1992. Available online at [www.fpnotebook.com/SUR88.htm](http://www.fpnotebook.com/SUR88.htm). Accessed May 27, 2003.
9. Williams C. Tegagen alginate dressing for moderate to heavily exuding wounds. *British Journal of Nursing*. 1998;7(9).
10. Bohnot S, Meaume S, Sayag J. Healing properties of calcium alginate dressings. *Journal of Wound Care*. 1996;5(8):357-362.
11. Timmons J. Alginates and hydrofibre dressings. *Professional Nurse*. 1999;14(7).
12. O'Donoghue J, O'Sullivan S, O'Shaughnessy M, O'Connor T. Effects of a silicone-coated polyamide net dressing and calcium alginate on the healing of split skin graft donor sites: A prospective randomised trial. *Acta Chir Plas*. 2000;42(1):3-6.
13. Bowler P, Jones S, Davies B, Coyle E. Infection control properties of some wound dressings. *Journal of Wound Care*. 1999;8(10):499-502.
14. Belmin J, Meaume S, Rabus, Bohbot M. Sequential treatment with calcium alginate dressings and hydrocolloid dressings accelerates pressure ulcer healing in older subjects: A multicenter randomized trial of sequential versus nonsequential treatment with hydrocolloid dressing alone. *Journal of the American Geriatrics Society*. 2002;50(2):269-74.
15. Kammerlander G, Andriessen A. An alginate dressing vs a hydrofiber dressing in the management of various wound types: A randomized controlled clinical trial. *Wound and Repair Regeneration*. 2000;5:A420.
16. Ichioka S, Harii K, Nakahara M, Sato Y. An experimental comparison of hydrocolloid and alginate dressings, and the effect of calcium ions on the behaviour of alginate gel. *Scandinavian Journal of Plastic Reconstructive Hand Surgery*. 1998;32(3):311-316.
17. Smith & Nephew. Allevyn Product Introduction. Available online at [www.wound.smith-nephew.com/ca](http://www.wound.smith-nephew.com/ca). Accessed January 12, 2004.
18. Banks V, et al. Evaluation of a new polyurethane foam dressing. *Journal of Wound Care*. 1997;6(6).
19. Calgitrol Foams. Product Description. Available online at [www.woundcare.org/newsvol6n1/pr10.htm](http://www.woundcare.org/newsvol6n1/pr10.htm). Accessed January 12, 2004.
20. Fletcher J. Exudate theory and the clinical management of exuding wounds. *Professional Nurse*. 2002;17(8).
21. Grocott P. Palliative management of fungating malignant wounds. *Journal of Community Nursing*. 2000;14(3).
22. Scott M. Foam dressing. *Family Practice Notebook 2004*. Available online at [www.fpnotebook.com/SUR103.htm](http://www.fpnotebook.com/SUR103.htm). Accessed January 12, 2004.
23. Glavan L, Barkauskas C, McIntosh A, Baranoski S, Limova M, Brown-Etris M, Hollowat A. Clinical evaluation of a new foam dressing in the management of venous insufficiency ulcers. Presentation at SAWC 2003. Available online at <http://cms.3m.com/cms/GB/en/289/kkceRFQ/view.jhtml>. Accessed May 27, 2003.
24. Dowsett C. Malignant fungating wounds: Assessment and management. *British Journal of Community Nursing*. 2002;7(8):394-400.
25. Krasner DL, Rodeheaver GT, Sibbald RG, (eds.). *Chronic Wound Care: A Clinical Source Book for Healthcare Professionals*, Third Edition. Wayne, PA: HMP Communications, 2001.
26. Sibbald G, Campbell K, Coutts P, Queen D. Intact skin—An integrity not to be lost. *Ostomy/Wound Management*. 2003;49(6):27-41.
27. McMurray V. Managing patients with fungating malignant wounds. *Nursing Times*. 2003;99(13).
28. Sibbald G, Williamson D, Orsted H, Campbell K, Keast D, Krasner D, Sibbald D. Preparing the wound bed: Debridement, bacterial balance, and moisture balance. *Ostomy/Wound Management*. 2000;46(11):14-35.
29. Hampson P. The use of Metronidazole in the treatment of malodorous wounds. *Journal of Wound Care*. 1996;5(9):421-6.
30. Collier M. The assessment of patients with malignant fungating wounds: A holistic approach. Part 1. *Nursing Times*. 1997;93(44): [Supplement 1]:1-4.
31. Winnipeg Regional Health Authority Wound Care Recommendations. WRHA Manual: Winnipeg, MB. June 2003.
32. Piggitt C. Malodorous fungating wounds: Uncertain concepts underlying the management of social isolation. *Int J Palliat Nurs*. 2003;9(5):216-21.
33. Naylor W. Symptom control of fungating wounds. *World Wide Wounds*. Feb 2002. Available online at [www.worldwidewounds.com/2002/marcg/Naylor/Symptom-Control-Fungating-Wounds.html](http://www.worldwidewounds.com/2002/marcg/Naylor/Symptom-Control-Fungating-Wounds.html). Accessed April 28, 2003.
34. Wilkes L. Malignant wound management: What dressings do nurses use? *Journal of Wound Care*. 2001;10(3).

## Honey, an Old Remedy ...

*continued from page 58*

### References

1. Molan PC. A brief review of honey as a clinical dressing. *Primary Intention*. 1998;6(4):148-58.
2. Molan PC. The role of honey in the management of wounds. *J Wound Care*. 1999;8(8):423-6.
3. Rund C. Alternative therapies for wound care. In Krasner DL, Rodeheaver GT, Sibbald RG, (eds.). *Chronic Wound Care: A Clinical Source Book for Healthcare Professionals*, Third Edition. Wayne PA: HMP Communications. 2001:329-340.
4. Subrahmanyam M. A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazide. *Burns*. 1998;24:157-61.
5. Molan PC. The antibacterial activity of honey: 1. The nature of the antibacterial activity. *Bee World*. 1992;73(1):5-28.
6. Chirife J, Hertzage L, Joseph A, Kohn ES. In vitro study of bacterial growth inhibition in concentrated sugar solutions: Microbiological basis for the use of sugar in treating infected wounds. *Antimicrob Agents Chemother*. 1983;23(5):766-73.
7. Willix DJ, Molan PC, Harfoot CJ. A comparison of the sensitivity of wound-infecting species of bacteria to the antibacterial activity of manuka honey and other honey. *J Appl Bacteriol*. 1992;73:388-94.
8. Cooper RA, Molan PC, Harding KG. Antibacterial activity of honey against strains of *Staphylococcus aureus* from infected wounds. *J R Soc Med*. 1999; 92:283-5.

## Literature Review *continued from page 46*

### Updated Guidelines Available

Rosser WW, Pennie RA, Pilla NJ, and the Anti-infective Review Panel. Anti-infective guidelines for community-acquired infections. Toronto: MUMS Guideline Clearinghouse; 2005. ([www.mumshealth.com](http://www.mumshealth.com))

The 10th anniversary edition of the Anti-infective guidelines for community-acquired infections—2005 is now available. This “orange book” is one in a series of guidelines developed by and for front-line clinicians. The Anti-infective Review Panel represents a mix of health professionals with expertise in several fields and who practise in a variety of clinical settings. In addition, the guidelines are peer-reviewed by hundreds of front-line health professionals in order to ensure a very practical and relevant document that is evidence-based and user-friendly.

To order a copy, visit [www.mumshealth.com](http://www.mumshealth.com), phone 416-597-6867, fax 416-597-8574, e-mail [guidelines@mumshealth.com](mailto:guidelines@mumshealth.com) or visit your closest university medical bookstore.